See today's BioWorld AsiaSee today's BioWorld
To read the full story, subscribe or sign in.

Neurocrine advances Nxera’s NBI-1117568 in schizophrenia

April 16, 2024
By Tamra Sami
Nxera Pharma Co. Ltd. announced that its partner, Neurocrine Biosciences Inc., is advancing NBI-1117568 to phase II trials for treatment of schizophrenia and other neuropsychiatric disorders.
BioWorld BioWorld Asia Clinical Regulatory Neurology/psychiatric Small molecule Asia-Pacific Japan U.S.